Reduced aSMase enzymatic activity has been described in PD patients with SMPD1 mutations, and loss of aSMase expression correlates with increased α-synuclein levels in vitro [73]; indeed SMPD1 mutations are associated with increased risk for PD [51]. The gene discussed is SMPD1; the disease is Parkinson disease.